PMA device
CustomFlex Artificial Iris
Humanoptics AG · Artificial Iris (QBT, Class III) · First FDA decision May 30, 2018, newest Oct 3, 2019
Last checked: Nov 20, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
3
Breakthrough-designated
Device trials
1
Naming "CustomFlex"
MAUDE reports
0
Brand "CustomFlex", since 2015
PubMed studies
9
Mentioning "CustomFlex"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing CustomFlex Artificial Iris
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 3 of 3 decisions filed under this name.
- CustomFlex Artificial IrisPMA supplement
P170039-S002 · Decided Oct 3, 2019 · 441 days after receipt · Normal 180 Day Track No User Fee
Device type: Artificial iris (QBT) · Ophthalmology
- CustomFlex Artificial IrisPMA supplement
P170039-S001 · Decided Sep 23, 2019 · 440 days after receipt · Normal 180 Day Track No User Fee
Device type: Artificial iris (QBT) · Ophthalmology
- CustomFlex Artificial IrisBreakthroughPMA
P170039 · Decided May 30, 2018 · 182 days after receipt
Device type: Artificial iris (QBT) · Ophthalmology
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
- Artificial Hearts and related devices, including Ventricular Assist Devices for Bridge-to-Transplant and Destination TherapyNational analysisReview closedCAG-00453NUpdated Nov 19, 2026
- Lumbar Artificial Disc Replacement (LADR)National determinationOn the books150.10Updated Nov 4, 2026
- Lumbar Artificial Disc Replacement (LADR)National analysisReview closedCAG-00292RUpdated Sep 18, 2026
- Lumbar Artificial Disc ReplacementNational analysisReview closedCAG-00292NUpdated Sep 18, 2026
- Artificial HeartsNational analysisReview closedCAG-00322NUpdated Sep 16, 2026
- Artificial Hearts and Related Devices - RETIREDNational determinationOn the books20.9Updated Jun 5, 2024
- Artificial Intelligence Enabled CT Based Quantitative Coronary Topography (AI-QCT)/Coronary Plaque Analysis (AI-CPA)Local determinationIn effectL39851Palmetto GBAUpdated Oct 7, 2026
- Artificial Intelligence Enabled CT Based Quantitative Coronary Topography (AI-QCT)/Coronary Plaque Analysis (AI-CPA)Local determinationIn effectL39863Wellpoint FederalUpdated Jul 14, 2026
Clinical trials
Device studies on ClinicalTrials.gov that name "CustomFlex", any status and sponsor, newest update first.
- Safety and Effectiveness of the CustomFlex Artificial Iris Prosthesis for the Treatment of Iris DefectsStatus unknown
Clinical Research Consultants, Inc.Not on our public-company list
NCT01860612 · 500 participants (planned) · Start Oct 2013 · Primary completion Dec 31, 2025
Device: Artificial Iris (CustomFlex) · For: Full Aniridia; Partial Aniridia
Sites: Los Angeles, California; Atlanta, Georgia; Indianapolis, Indiana · 13 sites in all
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "CustomFlex", and for the whole product code for context.
This brand
0 reports: 0 malfunction, 0 injury, 0 death
Whole product code QBT
0 reports: 0 malfunction, 0 injury, 0 death
Newest reports for this brand
No MAUDE reports name this brand.
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
No recall in FDA's data is linked to these FDA numbers.
Published research
The most relevant PubMed records for "CustomFlex"[tiab]. The summary above synthesizes these.
- Bilateral Artificial Iris implantation in patients with bilateral iris defects.
Mayer CS, Baur ID, Storr J, et al. · Am J Ophthalmol Case Rep · 2021Case Reports
- Slip-and-slide technique for combined small-incision artificial iris and IOL implantation.
Wolf A, Shajari M · J Cataract Refract Surg · 2020
- Anterior segment reconstruction with artificial iris and Descemet membrane endothelial keratoplasty: a staged surgical approach.
Ang M, Tan D · Br J Ophthalmol · 2022
- Management of aniridia and iris defects: an update on iris prosthesis options.
Weissbart SB, Ayres BD · Curr Opin Ophthalmol · 2016Review
- Traumatic iridodialysis and mydriasis: Surgical reconstruction of the iris-lens-diaphragm with an iris implant and Intraocular lens.
Baur ID, Mayer CS, Storr J, et al. · Am J Ophthalmol Case Rep · 2022Case Reports
- In-the-bag injection and overfold technique for custom flexible prosthetic iris prostheses.
Amaral HL, Snyder ME · J Cataract Refract Surg · 2022
- Results of the United States Food and Drug Administration Clinical Trial of the CustomFlex Artificial Iris.
Ayres BD, Fant BS, Landis ZC, et al. · Ophthalmology · 2022Clinical Trial, Multicenter Study
- The simultaneous treatment of post-traumatic aphakia, aniridia, and astigmatism.
Jürgens I, Dyrda A · Arch Soc Esp Oftalmol (Engl Ed) · 2026Case Reports
- Implantation of ArtificialIris, a CustomFlex irisprosthesis, in a trauma patient with an Artisan lens: A case report and review.
Doroodgar F, Jabbarvand M, Niazi F, et al. · Medicine (Baltimore) · 2017Case Reports
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.